Yasukata Ohashi1,2, Megumi Yatabe3, Daisuke Niijima3, Kentaro Tani3, Chiaki Ogawa3, Yutaka Yachi3, Toshiya Kagoo4, Saigen Boku4, Hironori Ueno4, Takahiro Yano4, Koji Higai2, Akihiro Yokoyama4,5. 1. Department of Pharmacy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan yasu970554126@gmail.com. 2. Laboratory of Medical Biochemistry, Faculty of Pharmaceutical Sciences Toho University, Chiba, Japan. 3. Department of Pharmacy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan. 4. Division of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan. 5. Division of Transfusion Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Abstract
BACKGROUND/AIM: Gastrointestinal toxicity is common in patients receiving common therapy of ixazomib with lenalidomide and low-dose dexamethasone (IRd) for relapsed/refractory multiple myeloma. Here, we investigated the safety and effectiveness of ixazomib dosing schedules. PATIENTS AND METHODS: We retrospectively evaluated 17 consecutive patients treated with IRd (10 patients on ixazomib dose-escalation strategy (2.3 mg starting dose); seven patients on standard dose). RESULTS: The incidence of grade 3 or more haematological and grade 2 or more non-haematological adverse events was lower in the dose-escalation group than in the standard-dose group, and only that of diarrhoea was significantly lower. The median time to treatment interruption was significantly longer in the dose-escalation group than in the standard-dose group. There was no significant difference in the overall response rate (20% vs. 43%) and disease control rate (70% vs. 86%). CONCLUSION: A dose-escalation strategy to optimise ixazomib dosing may reduce treatment interruption due to adverse events without compromising its antitumor activity. Copyright
BACKGROUND/AIM: Gastrointestinal toxicity is common in patients receiving common therapy of ixazomib with lenalidomide and low-dose dexamethasone (IRd) for relapsed/refractory multiple myeloma. Here, we investigated the safety and effectiveness of ixazomib dosing schedules. PATIENTS AND METHODS: We retrospectively evaluated 17 consecutive patients treated with IRd (10 patients on ixazomib dose-escalation strategy (2.3 mg starting dose); seven patients on standard dose). RESULTS: The incidence of grade 3 or more haematological and grade 2 or more non-haematological adverse events was lower in the dose-escalation group than in the standard-dose group, and only that of diarrhoea was significantly lower. The median time to treatment interruption was significantly longer in the dose-escalation group than in the standard-dose group. There was no significant difference in the overall response rate (20% vs. 43%) and disease control rate (70% vs. 86%). CONCLUSION: A dose-escalation strategy to optimise ixazomib dosing may reduce treatment interruption due to adverse events without compromising its antitumor activity. Copyright
Authors: Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David E Avigan; Wanling Xie; Irene M Ghobrial; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson Journal: Blood Date: 2010-04-12 Impact factor: 22.113
Authors: Shaji K Kumar; William I Bensinger; Todd M Zimmerman; Craig B Reeder; James R Berenson; Deborah Berg; Ai-Min Hui; Neeraj Gupta; Alessandra Di Bacco; Jiang Yu; Yaping Shou; Ruben Niesvizky Journal: Blood Date: 2014-06-05 Impact factor: 22.113
Authors: Shaji K Kumar; Jesus G Berdeja; Ruben Niesvizky; Sagar Lonial; Jacob P Laubach; Mehdi Hamadani; A Keith Stewart; Parameswaran Hari; Vivek Roy; Robert Vescio; Jonathan L Kaufman; Deborah Berg; Eileen Liao; Alessandra Di Bacco; Jose Estevam; Neeraj Gupta; Ai-Min Hui; Vincent Rajkumar; Paul G Richardson Journal: Lancet Oncol Date: 2014-11-14 Impact factor: 41.316
Authors: G M Blumenthal; Y Gong; K Kehl; P Mishra-Kalyani; K B Goldberg; S Khozin; P G Kluetz; G R Oxnard; R Pazdur Journal: Ann Oncol Date: 2019-05-01 Impact factor: 32.976
Authors: A Keith Stewart; S Vincent Rajkumar; Meletios A Dimopoulos; Tamás Masszi; Ivan Špička; Albert Oriol; Roman Hájek; Laura Rosiñol; David S Siegel; Georgi G Mihaylov; Vesselina Goranova-Marinova; Péter Rajnics; Aleksandr Suvorov; Ruben Niesvizky; Andrzej J Jakubowiak; Jesus F San-Miguel; Heinz Ludwig; Michael Wang; Vladimír Maisnar; Jiri Minarik; William I Bensinger; Maria-Victoria Mateos; Dina Ben-Yehuda; Vishal Kukreti; Naseem Zojwalla; Margaret E Tonda; Xinqun Yang; Biao Xing; Philippe Moreau; Antonio Palumbo Journal: N Engl J Med Date: 2014-12-06 Impact factor: 91.245
Authors: Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz Journal: Blood Date: 2007-11-01 Impact factor: 22.113
Authors: Clemens M Wendtner; Michael Hallek; Graeme A M Fraser; Anne-Sophie Michallet; Peter Hillmen; Jan Dürig; Matt Kalaycio; John G Gribben; Stephan Stilgenbauer; Andreas Buhler; Thomas J Kipps; Brendan Purse; Jennie Zhang; Sabine De Bedout; Jay Mei; Asher Chanan-Khan Journal: Leuk Lymphoma Date: 2016-01-14
Authors: C S Chim; S K Kumar; R Z Orlowski; G Cook; P G Richardson; M A Gertz; S Giralt; M V Mateos; X Leleu; K C Anderson Journal: Leukemia Date: 2017-11-16 Impact factor: 11.528
Authors: S Ozaki; H Handa; T Saitoh; H Murakami; M Itagaki; H Asaoku; K Suzuki; A Isoda; M Matsumoto; M Sawamura; J Konishi; K Sunami; N Takezako; S Hagiwara; Y Kuroda; T Chou; E Nagura; K Shimizu Journal: Blood Cancer J Date: 2015-09-18 Impact factor: 11.037